BlueOcean Ventures

Abionic SA develops disrupter nanotechnology based diagnostic solutions. The company develops abioSCOPE, a biomedical screening platform that allows users to test patients from a single drop of blood in record time; abioSCOPE, a reader that tests nano fluidic sensors; and abioGUIDE, an application for smartphones and tablets. Its products are used in clinical laboratories and at the point-of-care to improve medical diagnosis, and other applications in allergy and sepsis. Abionic SA has a strategic agreement with Genentech. The company was founded in 2010 and is based in Lausanne, Switzerland.

Augurix SA design, develops, and markets diagnostics devices to facilitate early diagnosis and confirmation of gastro-intestinal diseases. It offers Simtomax, an accurate test that helps medical professionals in screening Celiac Disease at the point of care from whole blood, serum, plasma, or saliva. The company’s Simtomax is used in physician practices, pharmacies and screening venues, and laboratories. It sells its product through distributors in Switzerland and internationally. The company was founded in 2004 and is based in Monthey, Switzerland.

DistalMotion develops medical devices that are used to perform minimal-invasive surgeries. Ricardo Beira founded it on February 23, 2012, with its headquarters in Lausanne in Switzerland.

99RetailStreet is a common commerce platform on cloud targeted at the large unorganized retail segment comprising of “Kiranas/ Kades”, Pharmacies and other consumer facing retail businesses in developing markets. It is built to enhance the retailers’ business through faster Sales Growth, better Financial Capabilities and improved Efficiency across the value chain.

Ava AG develops Ava, a sensor bracelet that is worn during the night, which measures physiological parameters and predicts a woman’s next fertile window and ovulation. Its bracelet displays fertile window and ovulation information on the accompanying phone application. The company was founded in 2014 and is based in Zurich, Switzerland. It has an additional office in Hong Kong.

Cyanoguard AG is a chemical technology company specialised in the development of novel toxin detection methods to improve environmental monitoring, food safety and health care in remote settings and locations. Its innovative technology enables fast and safe cyanide detection in food, waste water and other samples. Its method is selective and requires no special training and/or equipment. Equipped with the latest research, and with over six years of close collaboration with leading industry partners, the company is dedicated to resolve today's cyanide issues, offering fast and safe toxin detection in any setting at any time.

MIKAJAKI SA designs and develops automated multi patient ocular diagnostics platform. The company was founded in 2018 and is based in Plan-les-Ouates, Switzerland.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment. Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.

Rheon Medical SA develops adjustable glaucoma drainage systems. It also offers eyeWatch, an adjustable drainage device for treating glaucoma and eyePlate, a silicone drainage plate that connects outlet of eyeWatch device and allow the drainage of aqueous humor through the filtration of bleb forming. The company was founded in 2010 and is based in Lausanne, Switzerland.

At Official.fm, they develop powerful music promotion tools for you, whether you're an emerging artist or an accomplished label. They make it easy to manage a few tracks or a large catalog, create pages and players that look like you and share them across your favorite promotion platforms and social networks, all the while collecting insightful analytics. Improving your workflow is their top priority. Promoting your music with official.fm will always be free. Music promotion is an investment for you and it is one for us too. Now you also have the ability to sell directly music to your fans. Soon they will offer more ways for your to generate revenue from your music.

Abionic SA develops disrupter nanotechnology based diagnostic solutions. The company develops abioSCOPE, a biomedical screening platform that allows users to test patients from a single drop of blood in record time; abioSCOPE, a reader that tests nano fluidic sensors; and abioGUIDE, an application for smartphones and tablets. Its products are used in clinical laboratories and at the point-of-care to improve medical diagnosis, and other applications in allergy and sepsis. Abionic SA has a strategic agreement with Genentech. The company was founded in 2010 and is based in Lausanne, Switzerland.

Viroblock SA is a healthcare company, engages in the development and marketing of antiviral products. It offers respiratory FFP2 mask with a mechanism of action against enveloped viruses, including human and avian influenzas, the hepatitis B and C viruses, and the AIDS virus. Its products and technologies have various prophylactic and therapeutic applications. Viroblock SA was founded in 2005 and is based in Geneva, Switzerland.

Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area. The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation. ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.